Neuronetics Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

STIM$2.18+1.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

(In thousands)


· · Years ended December 31,
· · 2023 · · 2022 · · 2021
Cash flows from Operating activities: · · · ·
Net loss	$(30,189)	$(37,159)	$(31,193)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,006	1,648	1,060
Allowance for credit losses	390	341	763
Inventory impairment	1,905	—	—
Share-based compensation	7,319	8,746	7,869
Non-cash interest expense	634	709	715
Cost of rental units purchased by customers	—	92	203
Changes in certain assets and liabilities:
Accounts receivable, net	(8,831)	(6,658)	(3,817)
Inventory	(1,098)	(2,587)	(3,444)
Net investments in sales-type leases	1,193	1,114	324
Prepaid commission expense	(1,319)	(1,243)	(1,926)
Prepaid expenses and other assets	(2,845)	786	62
Accounts payable	2,029	(1,968)	276
Accrued expenses	(2,243)	6,604	910
Deferred revenue	(989)	(1,164)	215
Net Cash used in Operating activities	(32,038)	(30,739)	(27,983)

Cash flows from Investing activities:
Purchases of property and equipment and capitalized software	(2,369)	(3,269)	(2,353)
Repayment (issuance) of notes receivable	1,047	10,000	(7,486)
Net Cash (used in) provided by Investing activities	(1,322)	6,731	(9,839)

Cash flows from Financing activities:
Payments of debt issuance costs	(1,104)	(91)	—
Proceeds from issuance of long-term debt	25,000	—	—
Repayment of long-term debt	(1,200)	—	—
Proceeds from the issuance of common stock	—	—	80,972
Payments of common stock offering issuance cost	—	—	(401)
Proceeds from exercises of stock options	1	298	2,435
Net Cash provided by Financing activities	22,697	207	83,006
Net (decrease) increase in Cash and Cash equivalents	(10,663)	(23,801)	45,184
Cash and Cash equivalents, Beginning of Period	70,340	94,141	48,957
Cash and Cash equivalents, End of Period	$59,677	$70,340	$94,141
Supplemental disclosure of cash flow information:
Cash paid for interest	$4,790	$3,543	$3,304
Transfer of inventory to property and equipment	$210	$250	$601
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses	$239	$103	$273
Reduction of accounts receivable in current and long-term notes receivable	$6,468	$432	$2,514

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.